Pneumonia Clinical Trials

Find Pneumonia Clinical Trials Near You

The Role of Elastic Power in Predicting the Severity and Mortality in Adult Patients With Acute Respiratory Distress Syndrome Secondary to Pneumonia

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

the role of elastic power in the prediction of severity and mortality in adults with ARDS secondary to pneumonia

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

⁃ Age from 18 to 65 years (male or female). Patients fulfilling criteria of ARDS as per Berline definition who will be admitted to ICU , intubated and MV more than 48 hours will be included in this study.

⁃ Fulfillment of Criteria of readiness for ARDS as per Berline definition :

• an acute onset (\<1 week of a known clinical insult or new or worsening respiratory symptoms),

• respiratory failure not primarily due to hydrostatic edema,

• bilateral opacities on a chest radiograph (not fully explained by effusions, lobar or lung collapse, or nodules), and

• \<300 mmHg of the ratio of arterial partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2/FiO2) with 5 cm H2O of positive end-expiratory pressure (PEEP) or continuous positive airway pressure. To facilitate the estimation of the ARDS prognosis, the Berline definition classifies the severity of ARDS into 3 categories: mild (200 mmHg \< PaO2/FiO2 \< 300 mmHg), moderate (100 mm Hg \< PaO2/FiO2 \<200 mmHg), and severe (PaO2/FiO2 \< 100 mmHg).

Locations
Other Locations
Egypt
Banha University Hospital
RECRUITING
Banhā
Contact Information
Primary
Ahmed H Awad, MsC.ICU
ahmedhossam79@gmail.com
+971561707026
Backup
Samar R Mohamed
01287793991
Time Frame
Start Date: 2024-01-24
Estimated Completion Date: 2024-10-24
Participants
Target number of participants: 70
Treatments
mild to moderate ARDS
100 =\< PO2/FiO2 ratio \< 300
severe ARDS
100 \< PO2/FiO2 ratio
Sponsors
Leads: Benha University

This content was sourced from clinicaltrials.gov